Pembrolizumab monotherapy for advanced chordoma – Authors' reply

Jean Yves Blay; Nicolas Penel; Florence Duffaud; Emmanuelle Bompas; Christophe Massard; Sylvie Chevret

doi:10.1016/s1470-2045(23)00454-0

Letter2020

Ripretinib for advanced gastrointestinal stromal tumours – Authors' reply

Jean Yves Blay, Margaret von Mehren

Article2021

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.

Jean‐Luc Van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Michael Chisamore, Anran Wang, Andrew X. Zhu

Article2021

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.

Jean‐Luc Van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Michael Chisamore, Anran Wang, Andrew X. Zhu

Article2006

Authors' reply

S. Khanna, Eduard Vieta, Benjamin Lyons, F. Grossman, M. Eerdekens, Michelle Kramer

Article1977

Authors’ Reply

Robert O. Ritchie, Benjamin Francis, W.L. Server

Metallurgical Transactions A

Pembrolizumab monotherapy for advanced chordoma – Authors' reply

Discussion(0)

Related publications

Ripretinib for advanced gastrointestinal stromal tumours – Authors' reply

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.

Authors' reply

Authors’ Reply